Dry Age-Related Macular Degeneration: Recent Progress of Therapeutic approaches

Author(s): Noriyuki Kuno, Shinobu Fujii

Journal Name: Current Molecular Pharmacology

Volume 4 , Issue 3 , 2011

Become EABM
Become Reviewer
Call for Editor


Age-related macular degeneration (AMD) is a progressive retinal degenerative disease and a common cause of blindness. In AMD, there are two phenotypes; “atrophic (dry)” and “neovascular (wet)”. The former is characterized by the geographic atrophy due to death of retinal pigment epithelium, and the latter is developed due to choroidal neovascularization. While wet AMD can be treated by the inhibition of vascular endothelial growth factor or photodynamic therapy, so far there are no available treatments for dry AMD. Fortunately, understanding of pathogenesis in dry AMD has significantly been progressed and many candidates for the treatment of dry AMD have been introduced in clinical trials as well as preclinical stages. In this article, the progress of therapeutic approaches for dry AMD is reviewed.

Keywords: Age-related macular degeneration, complement, drusen, dry AMD, geographic atrophy, lipofuscin, retinal pigment epithelium

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Published on: 01 March, 2012
Page: [196 - 232]
Pages: 37
DOI: 10.2174/1874467211104030196
Price: $65

Article Metrics

PDF: 39